Scholarlink

<p>This Letter to the Editor evaluates Jense et al.’s (2025) study on MiniMizer ring-augmented Roux-en-Y gastric bypass (RYGB) for patients with BMI &gt; 50&#xa0;kg/m<sup>2</sup>. While the study demonstrates promising outcomes—35.2% total weight loss (TWL) at 2&#xa0;years and 83.3% diabetes remission—several limitations warrant discussion. Key concerns include (1) the absence of stratified data on ring diameters (6.5–8.0&#xa0;cm), which obscures optimal size selection for balancing efficacy and complication risks; (2) limited applicability to revisional surgery, a common need for super-obese patients; and (3) insufficient reporting of micronutrient deficiencies and quality-of-life impacts, critical for holistic patient care. Additionally, the lack of cost-effectiveness analysis leaves the MiniMizer ring’s economic justification unclear. We commend the authors’ rigorous methodology but propose future research to address these gaps through standardized ring sizing, inclusion of revisional cases, and comprehensive nutritional and economic evaluations. These refinements would enhance the evidence base for ring-augmented RYGB in high-risk populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Ring‑augmented Roux‑en‑Y Gastric Bypass with MiniMizer Ring is Effective and Safe in Patients with a BMI > 50 kg/m2

  • 期刊论文

  • 发表日期：

    2025年7月14日

查看全文
  • Fajar Ali,
  • Anousheh Malak,
  • Safia Wazir,
  • Alishba Fakhar,
  • Malghalara Jawad

摘要

This Letter to the Editor evaluates Jense et al.’s (2025) study on MiniMizer ring-augmented Roux-en-Y gastric bypass (RYGB) for patients with BMI > 50 kg/m2. While the study demonstrates promising outcomes—35.2% total weight loss (TWL) at 2 years and 83.3% diabetes remission—several limitations warrant discussion. Key concerns include (1) the absence of stratified data on ring diameters (6.5–8.0 cm), which obscures optimal size selection for balancing efficacy and complication risks; (2) limited applicability to revisional surgery, a common need for super-obese patients; and (3) insufficient reporting of micronutrient deficiencies and quality-of-life impacts, critical for holistic patient care. Additionally, the lack of cost-effectiveness analysis leaves the MiniMizer ring’s economic justification unclear. We commend the authors’ rigorous methodology but propose future research to address these gaps through standardized ring sizing, inclusion of revisional cases, and comprehensive nutritional and economic evaluations. These refinements would enhance the evidence base for ring-augmented RYGB in high-risk populations.